The global Biosimilar Monoclonal Antibodies market is expanding as pharmaceutical companies, hospitals, and clinics invest in advanced biosimilar therapies to address the rising incidence of oncology, autoimmune diseases, and chronic conditions while reducing healthcare costs. The market was valued at USD 12.78 billion in 2023 and is projected to reach USD 32.0 billion by 2032, growing at a...